


For personal use only



The Complete Patient Engagement Platform

Innovating Solutions for Medical Practices and Hospitals



**Annual General Meeting
July 2020**

JAYEX HEALTHCARE LTD
ASX : JHL

Our Company



For personal use only

1977
Jayex
Established

First LED information
system sold in UK
healthcare market

1990

Development
of D300 Patient
Call display

1996

Development of
Touchscreen
Kiosk

2004

D300 leads UK
market in Patient
Calling

2005

Acquired HL7
integration
capabilities

2012

Jayex launch in
Australia and
New Zealand

2014

IPO on ASX
Acquisition of
Appointuit

2015

Commence digitisation of
products into Jayex
Connect Platform

2018

2020
Full SaaS
model
launched



Financial year 2019






- **Growing revenue**
 - Revenue up 6.5% to \$7.18 million
 - SaaS recurring revenue is 26% of Total Revenue in FY19
 - Original On-Premise revenue underpins growing SaaS revenue
- **Cost alignment** due to restructure
 - Expenses down 17%
 - Margin improvement

\$m	FY19	FY18
Total Revenue	7.18	6.75
Revenue from SaaS	1.9	
	26%	
Revenue from On-Premise	5.3	
	74%	

Jayex Connect – at our core

The **first** all-in-one patient engagement platform

- On-premise + cloud based **SaaS** solutions:

-  Online appointment booking
-  Digital displays to simplify communication
-  Patient self check-in + mobile check-in
-  Targeted health messaging
-  GP Clinic customisable


- Platform for **growth via innovation**

- Roll-out of additional solutions, to capture greater market share and revenue per customer eg mobile check-in and telehealth opportunity with Lifespot



Mobile Check-in

- A **new module** of the Jayex Connect platform
- Enables easy and efficient patient check-in and helps with queue reduction in busy waiting rooms
- Simple, two-step patient check-in
- Improves patient experience
- Streamlines the check-in process
- Eases the workload of reception staff



COVID-19

- Jayex not immune from effects of COVID-19
- Well placed to weather the storm given industry Jayex operates in
- Benefited from government support in UK
 - Secured £600,000 (\$1.08m AUD) in funding
 - Ensures company will remain in favourable cash position in ST
 - Supports any loss of revenue and assists company in progressing development and technological roadmap




Trading update

- **Revenue stable at \$4.3m 1H 20**
 - SaaS revenue stable but new business sales down \$494k due to COVID
- **Cashflow and EPS positive**
- **Funding received due to COVID (Q2 20)** to further projects and helps business remain cashflow positive
- **Positive Outlook for 2020**
 - Expect SaaS recurring revenue to **double** as additional solutions are rolled out and existing/new customers take up new products


\$m	1H 20	1H 19
Revenue	4.3	4.6

Revenue by region



\$m	Q2 20	Q1 20
Operating cashflow	0.209	0.156
Investing cashflow	-	-
Financing cashflow	0.663	-
Increase/decrease in cashflow	0.872	0.156
Cash at end of period	1.309	0.437

For personal use only



JAYEX HEALTHCARE LTD (ASX:JHL)

Innovating Solutions for Medical Practices and Hospitals

Contact

Michael Boyd

Executive Chairman

+61447600888

Jayex Healthcare Limited

Level 4, 100 Albert Road

South Melbourne VIC 3205

Australia



For personal use only

Disclaimer

This Presentation dated 31 July 2020 has been prepared and issued by Jayex Healthcare Limited (ACN 119 122 477) ("Jayex" or "Company") to be provided only to select parties.

Risk warning

An investment in the Company carries a high degree of risk due to the nature and stage of development of its business. The Company is not a suitable investment for persons unable to sustain a loss of all or part of the sum invested. Investors should have the financial ability and willingness to accept this risk.

This presentation may contain forecasts and forward looking information. Such forecasts, projections and information are not a guarantee of future performance, involve unknown risks and uncertainties. Actual results and developments will almost certainly differ materially from those expressed or implied in this presentation. Jayex has not audited or investigated the accuracy or completeness of the information, statements and opinions contained in this presentation.

Accordingly, to the maximum extent permitted by applicable laws, Jayex and its advisers make no representation and can give no assurance, guarantee or warranty, express or implied, as to, and take no responsibility and assume no liability for, the authenticity, validity, accuracy, suitability or completeness of, or any errors in, or omission, from any information, statement or opinion contained in this presentation. Potential investors and others receiving this presentation should conduct their own investigation and perform their own analysis in order to satisfy themselves as to the accuracy and completeness of the information, statements and opinions contained in this presentation before making any investment decision.

Any offer to invest in the Company will only be extended to a person or entity if they have first satisfied the Company that they are a Sophisticated Investor in Australia (under the requirements of the Corporations Act).

access the offer where it would not contravene any applicable law.

Confidentiality of this document

This Presentation and any other information provided in connection with this Presentation is confidential to the Company. It is provided to prospective investors for the sole purpose of considering an investment in the Company and must not be copied, supplied, disseminated or disclosed by any recipient to any other person (other than an employee or professional adviser of the recipient who is bound to keep it confidential), without the Company's prior written consent.

The distribution of this Presentation in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this Presentation must seek advice on, and comply with, any such restrictions. Any person who receives a copy of this Presentation in circumstances where receipt of this Presentation is unlawful or unauthorised or requires the Company to take any additional steps, including registration, must not accept the copy of the Presentation and must immediately return it to the Company. Any failure to comply with restrictions on receipt or distribution of this Presentation may constitute a violation of applicable securities law. The Company specifically prohibits the redistribution or reproduction of this material in whole or in part without the written permission of the Company and the Company accepts no liability whatsoever for the actions of third parties in this respect.